Piotr Berkowicz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Piotr Berkowicz has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Stefan Chlopicki
Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland
4 shared publications - Agnieszka Jasztal
Jagiellonian Centre for Experimental Therapeutics (JCET) Jagiellonian University Kraków Poland
2 shared publications - Agnieszka Karaś
Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland
2 shared publications - Agnieszka Kij
Jagiellonian University, Jagiellonian Centre for Experimental Therapeutics (JCET), Krakow, Poland
2 shared publications - Filip Aleksander Fedak
Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland
2 shared publications - Grzegorz Kwiatkowski
Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland
2 shared publications
Latest Publications
- Open Access
- 10 June 2026
- Published by Elsevier in SSRN Electronic Journal
Pharmacokinetic and pharmacodynamic characterisation of a novel dual PDIA1 and PDIA3 inhibitor with antiplatelet activity
Aromatic sulphonamides of aziridine-2-carboxylic acid have been reported by our group as PDI inhibitors displaying anti-thrombotic effects. A new compound with the acronym C-3399 was selected as a lead inhibitor of protein disulfide isomerase 1 (PDIA1) and 3 (PDIA3) with proven effectiveness. However, its mechanism of action remains unclear due to the rapid hydrolysis of its ester moiety. Here, we aimed to characterise the pharmacokinetics and pharmacodynamics of C-3399 in more detail. The main metabolite of C-3399, carboxylic acid contractually designated as C-3399-B, was identified using high resolution mass spectrometry and was later synthesised for further investigation. Although parent compound and its metabolite inhibit PDI and human platelet activation, the metabolite potency was considerably weaker (IC50 18.79 µM - PDIA1 and > 50.00 µM - PDIA3) than that of the parent compound (IC50 7.47 µM - PDIA1 and 28.00 µM – PDIA3). Metabolite C-3399-B also displayed weaker anti-platelet activity but accumulated inside platelets, in contrast to the parent molecule. The binding mechanism predicted by induced-fit docking models suggested different binding sites within ‘a’ domain for C-3399 and C-3399-B. The pharmacokinetic profiles of C-3399 and C-3399-B in rats showed immediate hydrolysis of the ester moiety and rapid elimination of the metabolite (t0.5 = 25 min). In conclusion, the results of the study indicate that the pharmacological effects of C-3399 and its active metabolite C-3399-B afford combined PDI inhibition through covalent and noncovalent binding in both extracellular and intracellular space.
- 10 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPharmacokinetic and pharmacodynamic characterisation of a novel dual PDIA1 and PDIA3 inhibitor with antiplatelet activity
Aromatic sulphonamides of aziridine-2-carboxylic acid have been reported by our group as PDI inhibitors displaying anti-thrombotic effects. A new compound with the acronym C-3399 was selected as a lead inhibitor of protein disulfide isomerase 1 (PDIA1) and 3 (PDIA3) with proven effectiveness. However, its mechanism of action remains unclear due to the rapid hydrolysis of its ester moiety. Here, we aimed to characterise the pharmacokinetics and pharmacodynamics of C-3399 in more detail. The main metabolite of C-3399, carboxylic acid contractually designated as C-3399-B, was identified using high resolution mass spectrometry and was later synthesised for further investigation. Although parent compound and its metabolite inhibit PDI and human platelet activation, the metabolite potency was considerably weaker (IC50 18.79 µM - PDIA1 and > 50.00 µM - PDIA3) than that of the parent compound (IC50 7.47 µM - PDIA1 and 28.00 µM – PDIA3). Metabolite C-3399-B also displayed weaker anti-platelet activity but accumulated inside platelets, in contrast to the parent molecule. The binding mechanism predicted by induced-fit docking models suggested different binding sites within ‘a’ domain for C-3399 and C-3399-B. The pharmacokinetic profiles of C-3399 and C-3399-B in rats showed immediate hydrolysis of the ester moiety and rapid elimination of the metabolite (t0.5 = 25 min). In conclusion, the results of the study indicate that the pharmacological effects of C-3399 and its active metabolite C-3399-B afford combined PDI inhibition through covalent and noncovalent binding in both extracellular and intracellular space.
- Open Access
- 3 March 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Defects in auxiliary fuel oxidation and mitochondrial pyruvate transport mark transition to overt heart failure in Tgαq*44 mice
Background: Defective catabolism of alternative and glucose-sparing fuel sources has recently been implicated in the development of cardiovascular and metabolic diseases, including heart failure (HF), but the molecular mechanisms and a causal relationship linking them to altered glucose metabolism are unknown. Methods: Herein, alterations in cardiac protein expression in an established HF model (Tgαq*44 mice) were explored at different ages (4−14 months) in relation to changes in energy substrate preference, high-energy phosphate metabolism, and a snapshot of plasma metabolites. A small cohort of HF cases ( n = 20) and non-failing controls ( n = 18) was also used to confirm translational value of the findings. Results: The progression of HF in Tgαq*44 mice was characterised by an increased reliance on glucose along with reduced mitochondrial oxidative metabolism that was associated with impaired MPC (mitochondrial pyruvate carrier)−mediated pyruvate utilisation and redirection of glycolytic intermediates into the hexose monophosphate shunt, glycogenesis, and serine biosynthetic pathway. Defects in fatty acid (FA), pyruvate, branched-chain amino acid (BCAA), and ketone body (KB) oxidation, alongside prominent elevation of lactate, represented major features of altered cardiac metabolism in end-stage HF. Chronic accumulation of BCAAs next to suppressed KB and disrupted glucose oxidation were also found in patients with advanced HF, underlying the clinical relevance of the observed alterations. Conclusion: This study provides the comprehensive pattern of metabolic evolution of HF, highlighting several possible avenues to rescue from the HF-prone phenotype, such as promoting BCAA and KB catabolism, or normalising glucose utilisation by overexpressing MPC.
- 3 March 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessDefects in auxiliary fuel oxidation and mitochondrial pyruvate transport mark transition to overt heart failure in Tgαq*44 mice
Background: Defective catabolism of alternative and glucose-sparing fuel sources has recently been implicated in the development of cardiovascular and metabolic diseases, including heart failure (HF), but the molecular mechanisms and a causal relationship linking them to altered glucose metabolism are unknown. Methods: Herein, alterations in cardiac protein expression in an established HF model (Tgαq*44 mice) were explored at different ages (4−14 months) in relation to changes in energy substrate preference, high-energy phosphate metabolism, and a snapshot of plasma metabolites. A small cohort of HF cases ( n = 20) and non-failing controls ( n = 18) was also used to confirm translational value of the findings. Results: The progression of HF in Tgαq*44 mice was characterised by an increased reliance on glucose along with reduced mitochondrial oxidative metabolism that was associated with impaired MPC (mitochondrial pyruvate carrier)−mediated pyruvate utilisation and redirection of glycolytic intermediates into the hexose monophosphate shunt, glycogenesis, and serine biosynthetic pathway. Defects in fatty acid (FA), pyruvate, branched-chain amino acid (BCAA), and ketone body (KB) oxidation, alongside prominent elevation of lactate, represented major features of altered cardiac metabolism in end-stage HF. Chronic accumulation of BCAAs next to suppressed KB and disrupted glucose oxidation were also found in patients with advanced HF, underlying the clinical relevance of the observed alterations. Conclusion: This study provides the comprehensive pattern of metabolic evolution of HF, highlighting several possible avenues to rescue from the HF-prone phenotype, such as promoting BCAA and KB catabolism, or normalising glucose utilisation by overexpressing MPC.
- Open Access
- 17 April 2025
- Published by Springer Nature in GeroScience
- Vol. 47 (3) , 2673-2701
Effects of life-long hyperlipidaemia on age-dependent development of endothelial dysfunction in humanised dyslipidaemic mice
Little is known, how life-long hyperlipidaemia affects vascular ageing, before atherosclerosis. Here, we characterise effects of mild, life-long hyperlipidaemia on age-dependent endothelial dysfunction (ED) in humanised dyslipidaemia model of E3L.CETP mice. Vascular function was characterised using magnetic resonance imaging in vivo and wire myograph ex vivo. Plasma endothelial biomarkers and non-targeted proteomics in plasma and aorta were analysed. Early atherosclerosis lesions were occasionally present only in 40-week-old or older E3L.CETP mice. However, age-dependent ED developed earlier, in 14-week-old male and 22-week-old female E3L.CETP mice as compared with 40-week-old female and male C57BL/6J mice. Acetylcholine-induced vasodilation in 8-week-old E3L.CETP, especially female mice, was blocked by catalase and attributed to H2O2. In 8-week-old female E3L.CETP mice, changes in plasma proteome in response to hyperlipidaemia were modest, while in male mice a number of differentially expressed proteins were identified that were involved in oxidative stress response, inflammation and regulation of metabolic pathways. In contrast, in older E3L.CETP and C57BL/6J mice, either plasma or aortic proteome displayed similar pattern of vascular ageing, dominating over hyperlipidaemia-induced changes. Interestingly, in 48-week-old male but not female E3L.CETP mice, vascular mitochondrial functional response was impaired. Early resilience of hyperlipidaemia-induced detrimental effects in young female E3L.CETP mice on a functional level was associated with a switch in vasodilation mechanism, blunted systemic proteomic response in plasma and slower ED development as compared to male E3L.CETP mice. The results indicate that profile of early vascular response to risk factors in young age may determine level of ED in older age before atherosclerosis development.
- 17 April 2025
- Published by Springer Nature in GeroScience
- Vol. 47 (3) , 2673-2701
Open AccessEffects of life-long hyperlipidaemia on age-dependent development of endothelial dysfunction in humanised dyslipidaemic mice
Little is known, how life-long hyperlipidaemia affects vascular ageing, before atherosclerosis. Here, we characterise effects of mild, life-long hyperlipidaemia on age-dependent endothelial dysfunction (ED) in humanised dyslipidaemia model of E3L.CETP mice. Vascular function was characterised using magnetic resonance imaging in vivo and wire myograph ex vivo. Plasma endothelial biomarkers and non-targeted proteomics in plasma and aorta were analysed. Early atherosclerosis lesions were occasionally present only in 40-week-old or older E3L.CETP mice. However, age-dependent ED developed earlier, in 14-week-old male and 22-week-old female E3L.CETP mice as compared with 40-week-old female and male C57BL/6J mice. Acetylcholine-induced vasodilation in 8-week-old E3L.CETP, especially female mice, was blocked by catalase and attributed to H2O2. In 8-week-old female E3L.CETP mice, changes in plasma proteome in response to hyperlipidaemia were modest, while in male mice a number of differentially expressed proteins were identified that were involved in oxidative stress response, inflammation and regulation of metabolic pathways. In contrast, in older E3L.CETP and C57BL/6J mice, either plasma or aortic proteome displayed similar pattern of vascular ageing, dominating over hyperlipidaemia-induced changes. Interestingly, in 48-week-old male but not female E3L.CETP mice, vascular mitochondrial functional response was impaired. Early resilience of hyperlipidaemia-induced detrimental effects in young female E3L.CETP mice on a functional level was associated with a switch in vasodilation mechanism, blunted systemic proteomic response in plasma and slower ED development as compared to male E3L.CETP mice. The results indicate that profile of early vascular response to risk factors in young age may determine level of ED in older age before atherosclerosis development.
- Open Access
- 24 January 2023
- Published by Springer Nature in GeroScience
- Vol. 45 (3) , 1619-1648
Accelerated ageing and coronary microvascular dysfunction in chronic heart failure in Tgαq*44 mice
Age represents a major risk factor in heart failure (HF). However, the mechanisms linking ageing and HF are not clear. We aimed to identify the functional, morphological and transcriptomic changes that could be attributed to cardiac ageing in a model of slowly progressing HF in Tgαq*44 mice in reference to the cardiac ageing process in FVB mice. In FVB mice, ageing resulted in the impairment of diastolic cardiac function and in basal coronary flow (CF), perivascular and interstitial fibrosis without changes in the cardiac activity of angiotensin-converting enzyme (ACE) or aldosterone plasma concentration. In Tgαq*44 mice, HF progression was featured by the impairment of systolic and diastolic cardiac function and in basal CF that was associated with a distinct rearrangement of the capillary architecture, pronounced perivascular and interstitial fibrosis, progressive activation of cardiac ACE and systemic angiotensin-aldosterone-dependent pathways. Interestingly, cardiac ageing genes and processes were represented in Tgαq*44 mice not only in late but also in early phases of HF, as evidenced by cardiac transcriptome analysis. Thirty-four genes and 8 biological processes, identified as being ageing related, occurred early and persisted along HF progression in Tgαq*44 mice and were mostly associated with extracellular matrix remodelling and fibrosis compatible with perivascular fibrosis resulting in coronary microvascular dysfunction (CMD) in Tgαq*44 mice. In conclusion, accelerated and persistent cardiac ageing contributes to the pathophysiology of chronic HF in Tgαq*44 mice. In particular, prominent perivascular fibrosis of microcirculation resulting in CMD represents an accelerated cardiac ageing phenotype that requires targeted treatment in chronic HF.
- 24 January 2023
- Published by Springer Nature in GeroScience
- Vol. 45 (3) , 1619-1648
Open AccessAccelerated ageing and coronary microvascular dysfunction in chronic heart failure in Tgαq*44 mice
Age represents a major risk factor in heart failure (HF). However, the mechanisms linking ageing and HF are not clear. We aimed to identify the functional, morphological and transcriptomic changes that could be attributed to cardiac ageing in a model of slowly progressing HF in Tgαq*44 mice in reference to the cardiac ageing process in FVB mice. In FVB mice, ageing resulted in the impairment of diastolic cardiac function and in basal coronary flow (CF), perivascular and interstitial fibrosis without changes in the cardiac activity of angiotensin-converting enzyme (ACE) or aldosterone plasma concentration. In Tgαq*44 mice, HF progression was featured by the impairment of systolic and diastolic cardiac function and in basal CF that was associated with a distinct rearrangement of the capillary architecture, pronounced perivascular and interstitial fibrosis, progressive activation of cardiac ACE and systemic angiotensin-aldosterone-dependent pathways. Interestingly, cardiac ageing genes and processes were represented in Tgαq*44 mice not only in late but also in early phases of HF, as evidenced by cardiac transcriptome analysis. Thirty-four genes and 8 biological processes, identified as being ageing related, occurred early and persisted along HF progression in Tgαq*44 mice and were mostly associated with extracellular matrix remodelling and fibrosis compatible with perivascular fibrosis resulting in coronary microvascular dysfunction (CMD) in Tgαq*44 mice. In conclusion, accelerated and persistent cardiac ageing contributes to the pathophysiology of chronic HF in Tgαq*44 mice. In particular, prominent perivascular fibrosis of microcirculation resulting in CMD represents an accelerated cardiac ageing phenotype that requires targeted treatment in chronic HF.